ZHANG Yanzhen′s experience in treating gouty arthritis by stages
ZHANG Honghong1 WANG Jie1 CHEN Hui2 ZHANG Yanhzhen1▲#br#
1.Department of Rheumatology,Shunyi Hospital,Beijing Traditional Chinese Medicine Hospital,Beijing 100035,China;
2.Department of Traditional Chinese Medicine,731 Troop Hospital of China Aerospace Science and Industry,Beijing 100074,China
Gouty arthritis(GA)is a common rheumatoid immune disease.Western medicine has its limitations in treating gout.Traditional Chinese medicine has unique advantages in improving the clinical symptoms of GA and delaying the progression of the disease.Based on the study of the theories of ancient scholars and literature review,combining clinical practice and western gout staging,ZHANG Yanzhen,rheumatology department deputy chief physician who works in Shunyi Hospital,Beijing Traditional Chinese Medicine Hospital divides the pathological process of GA into acute stage,intermittent stage and chronic stage.In the acute stage,the syndrome of dampness and heat is more common.The treatment is to clear heat and remove dampness.The intermittent period is mixed with the deficiency and the pathogens,and it is necessary to fill the deficiency and reduce the pathogens.The chronic phase is characterized by the incidence of deficiency.It is treated by warming Yang and strengthening spleen as well as tonifying liver and kidney.ZHANG Yanzhen physician takes different treatments according to the characteristics of each syndrome type as well as attaching importance to the application of anti-inflammatory Chinese medicine and external treatments.The curative effect is remarkable.
Molla MD,Bekele A,Melka DS,et al.Hyperuricemia and Its Associated Factors Among Adult Staff Members of the Ethiopian Public Health Institute,Ethiopia[J].Int J Gen Med,2021,14:1437-1447.
[3]
Merriman TR.An update on the genetic architecture of hyperuricemia and gout[J].Arthritis Res Ther,2015,17(1):98.
Chen B,Li H,Ou G,et al.Curcumin attenuates MSU crystal-induced inflammation by inhibiting the degradation of IκBα and blocking mitochondrial damage[J].Arthritis Res Ther,2019,21(1):193.